Cover Image
市場調查報告書

膠原酶3:開發中產品分析

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 363134
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
膠原酶3:開發中產品分析 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H1 2018
出版日期: 2018年03月20日 內容資訊: 英文 53 Pages
簡介

本報告提供膠原酶3藥物的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

膠原酶3概要

治療藥的開發

膠原酶3:開發中的產品 - 各開發階段

膠原酶3:開發中的產品 - 治療範圍別

膠原酶3:開發中的產品 - 各適應症

膠原酶3:開發中產品概況

  • 初期階段的產品

膠原酶3:企業開發中的產品

膠原酶3:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

膠原酶3治療藥的開發企業

  • Paradigm Biopharmaceuticals Limited
  • Pfizer Inc.
  • 武田藥品工業

膠原酶3:藥物簡介

膠原酶3:暫停中的計劃

膠原酶3:中止開發的產品

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1382TDB

Summary:

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules. The latest report Collagenase 3 - Pipeline Review, H1 2018, outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.

The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 1 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Toxicology, Central Nervous System, Infectious Disease and Respiratory which include indications Osteoarthritis, Chemotherapy Induced Peripheral Neuropathy, Allergic Asthma, Alphavirus Infections, Arthralgia, Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.

Furthermore, this report also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
  • Paradigm Biopharmaceuticals Ltd
  • Pfizer Inc
  • Takeda Pharmaceutical Co Ltd
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
  • pentosan polysulfate sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-152 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MMP2,9 and 13 for Myocardial Infarction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZF-198 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZF-760 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
  • Featured News & Press Releases
  • Mar 01, 2018: Paradigm Reports Osteoarthritis Pain Reduced by 50%
  • Jan 24, 2018: Current and past elite sportspeople successfully treated with PPS
  • Jan 16, 2018: European Patent Granted for Bone Marrow Edema Lesions
  • Nov 23, 2017: Paradigm's Two Arthritis Phase 2 Clinical Trials on Schedule
  • Nov 14, 2017: Paradigm Reports Successful Phase 2a BML/ACL Clinical Trial Results
  • Oct 30, 2017: First Participant Successfully Dosed in Phase 2b Clinical Trial for Osteoarthritis
  • Sep 19, 2017: Ethics Approval Received for Phase 2b Clinical Trial for Osteoarthritis
  • Sep 14, 2017: Paradigm Biopharmaceuticals: Significant momentum with Phase 2 Ross River Virus Clinical Trial
  • Sep 11, 2017: A Paradigm Shift in Treating Osteoarthritis Pain
  • Aug 09, 2017: Paradigm Successfully Doses First Participant in Phase 2 Ross River Virus Clinical Trial
  • Jul 10, 2017: Paradigm to Commence Phase 2 Ross River Virus Clinical Trial
  • May 16, 2017: Paradigm's preclinical hay fever trial: peer-reviewed and published in leading scientific journal
  • Mar 23, 2017: Paradigm Biopharmaceuticals Announces Final participant treated in Phase 2 hay fever trial
  • Mar 07, 2017: The Australian Company Testing a Breakthrough Treatment for Ross River
  • Nov 22, 2016: Paradigm Phase 2 Hay Fever Trialgets Approval from Swedish MPA
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018
  • Pipeline by Pfizer Inc, H1 2018
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top